reliable disease models [11] [12] [13] [14] . We have established iPSC lines from two LEOPARD syndrome patients, a 25-year-old female (L1) and a 34-year-old male (L2). A heterozygous T468M substitution mutation in PTPN11 is present in both.
Fibroblasts were transduced with OCT4-, SOX2-, KLF4-and MYCencoding VSV-pseudotyped Moloney-based retroviral vectors. Compact embryonic stem (ES)-cell-like colonies emerged after 2 weeks and TRA1-81-positive colonies were clonally expanded to create stable LEOPARD syndrome iPSC lines ( Supplementary Fig. 1) 8 . Three iPSC lines per patient were used for preliminary characterization: L1-iPS1, L1-iPS6, L1-iPS13, L2-iPS6, L2-iPS16 and L2-iPS18.
To verify that the iPSCs originated from patient-derived fibroblasts, we performed DNA fingerprinting analysis ( Supplementary Fig. 2a ). All iPSCs had normal karyotypes of 46,XX (L1) and 46,XY (L2) ( Supplementary Fig. 2b and data not shown). In addition, they carried the expected T468M mutation ( Supplementary Fig. 3a ). Restriction fragment length polymorphism analysis of a polymerase chain reaction with reverse transcription (RT-PCR) amplimer containing the mutation with BsmFI showed biallelic expression of PTPN11 (Supplementary Fig. 3b ). PCR and Southern blot analysis indicated the presence of all four transgene proviruses in the LEOPARD syndrome iPSCs ( Supplementary Fig. 4 ), and quantitative RT-PCR (qRT-PCR) results confirmed efficient transgene silencing ( Supplementary Fig. 5 ).
To characterize further the LEOPARD syndrome iPSC clones, expression of several human ES-cell markers in two LEOPARD syndrome iPSC lines from each patient (L1-iPS1, L1-iPS13, L2-iPS6 and L2-iPS16) was analysed and compared to the HES2 human ES cell line and a wild-type iPSC line, BJ-iPSB5, derived in our laboratory from a normal human fibroblast line (BJ). The BJ-iPSB5 cell line was also karyotypically normal (46,XY), and contained all four transgene proviruses, which were silenced ( Supplementary Figs 2b, 4b and 5b ). All LEOPARD syndrome and control iPSC lines showed high alkaline phosphatase activity and expressed pluripotency markers, including surface antigens TRA1-81, TRA1-60 and SSEA4, as well as the nuclear transcription factors OCT4 and NANOG ( Supplementary Fig. 6 ). Activation of a series of endogenous stemness genes (OCT4, NANOG, SOX2, GDF3, DPPA4, REX1 and TERT) in iPSCs was confirmed by qRT-PCR ( Fig. 1a and Supplementary Fig. 7a ). Extensive demethylation of CpG dinucleotides in the OCT4 and NANOG promoters compared to their parental fibroblasts was confirmed by bisulphite sequencing (Fig. 1b ).
We next examined genome-wide messenger RNA expression profiles of two LEOPARD syndrome iPSC lines from each patient, the BJ-iPSB5 cell line, parental fibroblasts and HES2 cells. The resulting heat map and scatter-plot analyses indicated that iPSC lines shared a higher degree of similarity with HES2 cells than with their parental fibroblast cell lines ( Fig. 1c and Supplementary Fig. 7b ).
Pluripotent human ES cells can differentiate into cell types representative of all three germ layers. We tested the differentiation abilities of our iPSCs using an in vitro floating embryoid body (EB) system, followed by replating on gelatin-coated dishes 10, 15 . Immunocytochemistry analyses detected expression of a-smooth muscle actin (a-SMA, mesoderm), desmin (mesoderm), a-fetoprotein (AFP, endoderm), vimentin (mesoderm), glia fibrillary acidic protein (GFAP, ectoderm) and bIII-tubulin (ectoderm) markers ( Fig. 2a and Supplementary Fig. 8 ). To determine pluripotency in vivo, we injected LEOPARD syndrome iPSCs, BJ-iPSB5 and HES2 cells into all three germ layers. a, L2-iPS6 cells were differentiated as floating EBs for 8 days and then plated onto gelatin-coated dishes and allowed to differentiate for another 8 days. Immunocytochemistry showed cell types positively stained for differentiation markers including desmin/a-SMA (mesoderm), AFP (endoderm), vimentin (mesoderm) and GFAP/bIII-tubulin (ectoderm). The arrow indicates a bIII-tubulin-positive cell. Scale bar, 100 mm. b, HES2, L1-iPSC and L2-iPSC were injected subcutaneously into the right hind leg of immuno-compromised NOD-SCID mice. The resulting teratomas were stained with haematoxylin and eosin and tissues representative of all three germ layers were observed. Scale bar, 100 mm.
immuno-compromised NOD-SCID mice. Histological analyses of the resulting teratomas showed cell types representative of the three germ layers, including pigmented cells (ectoderm), lung, respiratory and gut-like epithelia (endoderm), and mesenchyme, adipose tissue and cartilage (mesoderm) ( Fig. 2b and data not shown).
As mentioned previously, hypertrophic cardiomyopathy is one of the major features of LEOPARD syndrome, affecting 80% of the patients. In addition, affected individuals occasionally manifest haematological complications such as myelodysplasia and leukaemia 16, 17 . Therefore, we asked if LEOPARD syndrome iPSCs were able to differentiate into haematopoietic and cardiac lineages. iPSCs from both patients differentiated into a variety of haematopoietic cell types including early haematopoietic progenitors (CD41 1 ) 18 , early erythroblasts (CD71 1 /CD235a 1 ) 19 and macrophages (CD11b 1 ) 20 (Supplementary Fig. 9 and data not shown). The cardiac hypertrophic response includes induction of immediate-early genes (such as JUN, FOS and MYC), an increase in cell size, and organization of contractile proteins into sarcomeric units 21, 22 . To have an appropriate control cell line to analyse some of these parameters, besides human ES cells, we generated a wild-type iPSC line (S3-iPS4) from fibroblasts obtained from an unaffected brother of L1 without the T468M mutation ( Supplementary Figs 10 and 11 ). Using a well-established cardiac differentiation protocol 23 , we observed contracting EBs emerging around day 11 of differentiation (Supplementary Movies 1-7). To monitor cardiac development, we analysed cardiac troponin T (cTNT) expression on day 18 of differentiation by flow cytometry (data not shown). Replated cells from beating EBs were processed as described in Methods. Briefly, cells were fixed, immunostained for cTNT ( Fig. 3b ) and 50 cardiomyocytes were randomly chosen from each sample for surface area measurement using a computerized morphometric system (ImageJ software, NIH). Cardiomyocytes derived from LEOPARD syndrome iPSC lines L1-iPS13, L1-iPS6 and L2-iPS10 ( Supplementary Fig. 10 and Supplementary Fig. 11 ) had a significantly increased median surface area compared to wild-type iPSC cardiomyocytes (1.8 times, 2.5 times and 4.8 times larger, respectively), whereas the area median of the cardiomyocytes obtained from human ES cells was similar to wild-type iPSC cardiomyocytes (Fig. 3a ). We also observed increased sarcomere assembly in L1-iPS6 and L2-iPS10 cells when compared to wild-type S3-iPS4 cells (Fig. 3b) . Recently, the calcineurin-NFAT pathway has been shown to be an important regulator of cardiac hypertrophy. Active calcineurin dephosphorylates NFAT transcription factors, resulting in their nuclear translocation 22, 24 . We analysed the localization of NFATC4 using immunocytochemistry in 50 cTNT-positive cardiomyocytes derived from the L2-iPS10 cell line, which produced the largest cardiomyocytes, and wild-type S3-iPS4. We observed a significantly higher proportion of LEOPARD syndrome cardiomyocytes with nuclear NFATC4 (,80% versus ,30%, respectively; Fig. 3c, d) .
To identify potential molecular targets that could be affected by the T468M PTPN11 mutation, protein extracts from LEOPARD syndrome iPSCs, wild-type BJ-iPSB5 and HES2 cells were analysed using a phosphoproteomic microarray chip containing approximately 600 pan and phospho-specific antibodies (Kinexus Bioinformatics Corporation). We established eight groups for comparison, each of the LEOPARD syndrome iPSC lines versus one control cell line, either HES2 or wild-type iPSCs. Proteins with a 1.5-fold change were filtered, and those that were conserved in most of the groups were represented in a heat map (Fig. 4a) . Some of the proteins were more abundantly present in LEOPARD syndrome iPSCs when compared to either HES2 cells (DDR2, TYK2 and haspin) or wild-type iPSCs (p-MARCKs, p-synapsin 1, p-GRIN2B, p-RPS6KA5, p-RSK1/3 and p-p53). The phosphorylation of other proteins was increased (pcaveolin 2, p-MEK1, p-EGFR and p-FAK) or decreased (p-vinculin, p-S6 and p-LCK) in LEOPARD syndrome iPSCs when compared to control cell lines. To eliminate false positives, we verified the phosphoproteomic results by western blot for three of the most altered proteins (p-S6, p-EGFR and p-MEK1) in four LEOPARD syndrome iPSC lines, in comparison to wild-type iPSCs. Although we did not confirm a major change in the phosphorylation status of S6 protein (data not shown), western blot confirmed that the phosphorylation of EGFR and MEK1 proteins was considerably increased in the LEOPARD syndrome iPSC samples (Fig. 4b) .
RAS-mitogen-activated protein kinase (MAPK) represents the major signalling pathway deregulated by SHP2 mutants. Noonan syndrome mutants increase basal and stimulated phosphatase activity, whereas LEOPARD syndrome mutants are catalytically impaired and have dominant-negative effects, inhibiting growth-factor-evoked ERK1/2 activation 25 . We analysed the ability of LEOPARD syndrome iPSCs to respond to external growth factors. We used basic fibroblast growth factor (bFGF), the main growth factor in the maintenance of human ES cells, to induce the stimulation of the MAPK signalling pathway. bFGF treatment increased the phosphorylation of ERK1/2 (p-ERK) levels over time in HES2 and wild-type S3-iPS4 cells (Fig. 4c ). Although the LEOPARD syndrome iPSCs expressed the four FGF receptor (FGFR) family members ( Supplementary Fig. 12a ), bFGF stimulation did not cause any substantial change in p-ERK levels ( Fig. 4c and Supplementary Fig. 12b, c) . However, the LEOPARD syndrome iPSC lines had higher basal p-ERK levels compared to HES2 and S3-iPS4 cells ( Fig. 4c and Supplementary Fig. 12b, c) , in accordance with the increased p-MEK1-the upstream kinase of ERK-levels found in LEOPARD syndrome iPSC samples in phosphoproteomic array results. We have generated and characterized LEOPARD syndrome patientspecific iPSCs, providing a new system for the study of disease pathogenesis. Some of the standard procedures to analyse cardiomyocyte hypertrophy (for example, protein synthesis rate, re-activation of the fetal gene program) could not be reliably assessed due to the variably mixed population of cells obtained using this cardiac differentiation procedure (for example, endothelial, cardiomyocytes), and the lack of a reliable cell surface marker for cardiomyocyte purification. However, we observed increases in cell size, sarcomeric organization and nuclear NFATC4 localization in LEOPARD syndrome iPSC-derived cardiomyocytes, when compared to human ES cell and wild-type iPSCderived cardiomyocytes. These results would be consistent with cardiac hypertrophy, a condition commonly found in LEOPARD syndrome patients 2 , and indicate that this abnormality occurs through a cell-autonomous mechanism due to the PTPN11 mutation. Because many human cell types, such as cardiomyocytes, cannot be propagated readily in cell culture, iPSC-derived cells exhibiting disease-relevant phenotypes provide the requisite resource for precisely elucidating pathogenesis and pursuing novel therapeutic strategies.
In our studies, we also attempted to provide insights into the molecular events that could be affected by the PTPN11 mutation in the pluripotent iPSCs using antibody microarrays. We found that the phosphorylation of certain proteins was increased in LEOPARD syndrome iPSCs when compared to wild-type human ES cells and iPSCs. Further analysis will be required to elucidate if these proteins/signalling pathways are involved in the development of the disease phenotype. Notably, one of the more upregulated phosphoproteins was MEK1, the upstream kinase of ERK1/2, the gene of which is sometimes mutated in the related disorder cardiofaciocutaneous syndrome. PTPN11 mutations underlie 45% and 90% of Noonan syndrome and LEOPARD syndrome, respectively. It is not well understood how mutations that provoke opposite effects on SHP2 phosphatase activity cause syndromes with similar features 26 . In concordance with observations in the Drosophila LEOPARD syndrome model 7 , basal p-ERK levels were increased in LEOPARD syndrome iPSCs. Of note, receptor tyrosine kinase stimulation with bFGF in LEOPARD syndrome iPSCs failed to elicit further activation of ERK, as previously observed in a different cellular model 25 . This result demonstrates that RAS-MAPK signal transduction is perturbed in LEOPARD syndrome as early as the pluripotent stem-cell stage. Taken together, this is, to our knowledge, the first described human model of an inherited RAS pathway disorder. extracts of two iPSCs from each LEOPARD syndrome patient (L1 and L2), wild-type iPSCs (BJ-iPSB5) and HES2 cells were hybridized to an antibody microarray. The heat map represents the most significant protein changes preserved in all the comparison groups. b, p-MEK1 and p-EGFR expression was confirmed by western blot using phospho-specific antibodies. Band density was measured (ImageJ software) and normalized to b-actin. c, HES2, wild-type S3-iPS4 and LEOPARD syndrome iPSCs were serum-and bFGFstarved for 6 h and then treated with bFGF (20 ng ml 21 ) for the indicated time. Phosphorylated ERK1/2 (p-ERK1/2) and total ERK were assessed by immunoblotting and quantified. p-ERK1/2 levels were compared to the untreated p-ERK1/2 level in each sample, normalized to the total ERK1/2 and represented graphically at the right of each panel.
METHODS SUMMARY
Cell culture. Dermal fibroblast lines were obtained from skin biopsies, collected under an Institutional Review Board-approved protocol and with informed consent. Fibroblasts and GP2 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum and penicillin/ streptomycin (Invitrogen). HES2 cells and iPSCs were maintained on irradiated Swiss-Webster mouse embryonic feeder cells (MEFs), in a serum-free human ES cell medium containing 20 ng ml 21 bFGF (R&D Systems). LEOPARD syndrome iPSC generation. OCT4, SOX2, KLF4 and MYC transcription factors were introduced in dermal fibroblasts derived from two patients with LEOPARD syndrome via the pMXs retroviral vector. In parallel, the pMXs-EGFP vector was used to estimate the infection efficiency (data not shown). Six days after infection, fibroblasts were seeded onto MEFs. The following day the medium was replaced with the human ES cell medium and bFGF. Microarray analysis. Gene-level mRNA abundance measures were extracted using the Affymetrix GeneChip Exon 1.0 ST array, and Robust Multi-Array (RMA)-normalized using the Affymetrix Expression Console software. Subsequently, these genes were clustered and a heat map was generated against a background subset of genes showing at least twofold change between sample averages of iPSC/HES2 cells and fibroblast samples. In vitro differentiation. For non-lineage-specific and haematopoietic differentiation we used previously described protocols 10, 15, 27 , with certain modifications 28 . For cardiomyocyte induction, we used a well-established assay 23 . Phosphoproteomics. HES2 cells and iPSCs were incubated overnight in human ES cell culture medium deprived of bFGF and knockout serum replacement (KSR). Protein lysates were quantified by Bradford assay and sent to Kinexus Bioinformatics Corporation for antibody microarray screening. The proteins with at least 1.5-fold change between the LEOPARD syndrome iPSC samples and control sample (either HES2 or wt-iPSC), and conserved in the majority of the comparison groups, were represented in a heat map.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
